Literature DB >> 7540171

Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII.

J F Healey1, I M Lubin, H Nakai, E L Saenko, L W Hoyer, D Scandella, P Lollar.   

Abstract

The A2 domain (residues 373-740) of human blood coagulation factor VIII (fVIII) contains a major epitope for inhibitory alloantibodies and autoantibodies. We took advantage of the differential reactivity of inhibitory antibodies with human and porcine fVIII and mapped a major determinant of the A2 epitope by using a series of active recombinant hybrid human/porcine fVIII molecules. Hybrids containing a substitution of porcine sequence at segment 410-508, 445-508, or 484-508 of the human A2 domain were not inhibited by a murine monoclonal antibody A2 inhibitory, mAb 413, whereas hybrids containing substitutions at 387-403, 387-444, and 387-468 were inhibited by mAb 413. This indicates that the segment bounded by Arg484 and Ile508 contains a major determinant of the A2 epitope. mAb 413 did not inhibit two more hybrids that contained porcine substitutions at residues 484-488 and 489-508, indicating that amino acid side chains on both sides of the Ser488-Arg489 bond within the Arg484-Ile508 segment contribute to the A2 epitope. The 484-508, 484-488, and 489-508 porcine substitution hybrids displayed decreased inhibition by A2 inhibitors from four patient plasmas, suggesting that there is little variation in the structure of the A2 epitope in the inhibitor population.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540171     DOI: 10.1074/jbc.270.24.14505

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Contribution of A1 subunit residue Q316 in thrombin-activated factor VIII to A2 subunit dissociation.

Authors:  Ernest T Parker; Pete Lollar
Journal:  Biochemistry       Date:  2007-08-04       Impact factor: 3.162

2.  Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.

Authors:  Joerg Kahle; Aleksander Orlowski; Diana Stichel; John F Healey; Ernest T Parker; Marc Jacquemin; Manuela Krause; Andreas Tiede; Dirk Schwabe; Pete Lollar; Christoph Königs
Journal:  Blood       Date:  2017-05-15       Impact factor: 22.113

3.  Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.

Authors:  P M Zakas; K Vanijcharoenkarn; R C Markovitz; S L Meeks; C B Doering
Journal:  J Thromb Haemost       Date:  2014-11-11       Impact factor: 5.824

4.  Evidence That Factor VIII Forms a Bivalent Complex with the Low Density Lipoprotein (LDL) Receptor-related Protein 1 (LRP1): IDENTIFICATION OF CLUSTER IV ON LRP1 AS THE MAJOR BINDING SITE.

Authors:  Patricia A Young; Mary Migliorini; Dudley K Strickland
Journal:  J Biol Chem       Date:  2016-10-29       Impact factor: 5.157

5.  A discontinuous autoinhibitory module masks the A1 domain of von Willebrand factor.

Authors:  W Deng; Y Wang; S A Druzak; J F Healey; A K Syed; P Lollar; R Li
Journal:  J Thromb Haemost       Date:  2017-08-09       Impact factor: 5.824

Review 6.  Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies.

Authors:  Géraldine Lavigne-Lissalde; Chantal Rothschild; Claire Pouplard; Priscilla Lapalud; Yves Gruel; Jean-François Schved; Claude Granier
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

Review 7.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

8.  Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain.

Authors:  Keiji Nogami; Midori Shima; John C Giddings; Masahiro Takeyama; Ichiro Tanaka; Akira Yoshioka
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

9.  The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice.

Authors:  John F Healey; Ernest T Parker; Rachel T Barrow; Travis J Langley; William R Church; Pete Lollar
Journal:  Thromb Haemost       Date:  2009-07       Impact factor: 5.249

10.  The diversity of the immune response to the A2 domain of human factor VIII.

Authors:  Rebecca C Markovitz; John F Healey; Ernest T Parker; Shannon L Meeks; Pete Lollar
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.